Monday, April 06, 2020 9:18:03 AM
North
Great thoughts and appreciate your input.
As you stated , you don’t know how to separate V vs g sales.
I’m a pharmacist and never in my 28 years of practice have I seen where a pharmacist must dispense molecule a brand X for one indication and molecule a brand Y for another indication but here is the closest thing I’ve seen:
Bupropion (generic name of a chemical that had benefits for depression and smoking cessation).
Many insurance companies would not cover for a smoking cessation medication but would pay for an antidepressant. The manufacturer distributed the drug under two different brand names. Zyban was the name of the drug for smoking cessation and Wellbutrin was the name for depression. If a physician was prescribing for depression he was supposed to use Wellbutrin. Zyban for smoking.
The problem became that when the insurance company rejected Zyban because they did not cover smoking cessation products in general the prescriber would just change to Wellbutrin and claim depression.
What if in your arrangement H and R agreed to sell their drug under a different name like TrigBan? An agreement is reached that the 2 not be listed as interchangeable with the FDA. Pharmacists would have to give what is prescribed. H and R get VHTG market and Amarin keeps CVD.
Great thoughts and appreciate your input.
As you stated , you don’t know how to separate V vs g sales.
I’m a pharmacist and never in my 28 years of practice have I seen where a pharmacist must dispense molecule a brand X for one indication and molecule a brand Y for another indication but here is the closest thing I’ve seen:
Bupropion (generic name of a chemical that had benefits for depression and smoking cessation).
Many insurance companies would not cover for a smoking cessation medication but would pay for an antidepressant. The manufacturer distributed the drug under two different brand names. Zyban was the name of the drug for smoking cessation and Wellbutrin was the name for depression. If a physician was prescribing for depression he was supposed to use Wellbutrin. Zyban for smoking.
The problem became that when the insurance company rejected Zyban because they did not cover smoking cessation products in general the prescriber would just change to Wellbutrin and claim depression.
What if in your arrangement H and R agreed to sell their drug under a different name like TrigBan? An agreement is reached that the 2 not be listed as interchangeable with the FDA. Pharmacists would have to give what is prescribed. H and R get VHTG market and Amarin keeps CVD.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
